- Home
- VNOM vs ADMA Comparison
VNOM vs ADMA Comparison
Compare VNOM & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNOM
- ADMA
- Stock Information
- Founded
- VNOM 2013
- ADMA 2004
- Country
- VNOM United States
- ADMA United States
- Employees
- VNOM N/A
- ADMA N/A
- Industry
- VNOM Oil & Gas Production
- ADMA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VNOM Energy
- ADMA Health Care
- Exchange
- VNOM Nasdaq
- ADMA Nasdaq
- Market Cap
- VNOM 4.9B
- ADMA 4.1B
- IPO Year
- VNOM 2014
- ADMA N/A
- Fundamental
- Price
- VNOM $41.37
- ADMA $21.31
- Analyst Decision
- VNOM Strong Buy
- ADMA Strong Buy
- Analyst Count
- VNOM 13
- ADMA 4
- Target Price
- VNOM $58.46
- ADMA $22.50
- AVG Volume (30 Days)
- VNOM 1.7M
- ADMA 3.7M
- Earning Date
- VNOM 05-05-2025
- ADMA 05-08-2025
- Dividend Yield
- VNOM 6.02%
- ADMA N/A
- EPS Growth
- VNOM 42.01
- ADMA N/A
- EPS
- VNOM 3.82
- ADMA 0.81
- Revenue
- VNOM $817,200,000.00
- ADMA $426,454,000.00
- Revenue This Year
- VNOM $56.14
- ADMA $18.45
- Revenue Next Year
- VNOM $19.20
- ADMA $26.96
- P/E Ratio
- VNOM $10.83
- ADMA $26.31
- Revenue Growth
- VNOM 3.34
- ADMA 65.16
- 52 Week Low
- VNOM $34.71
- ADMA $6.01
- 52 Week High
- VNOM $56.76
- ADMA $23.64
- Technical
- Relative Strength Index (RSI)
- VNOM 49.81
- ADMA 60.16
- Support Level
- VNOM $35.60
- ADMA $17.30
- Resistance Level
- VNOM $38.65
- ADMA $22.25
- Average True Range (ATR)
- VNOM 2.43
- ADMA 1.50
- MACD
- VNOM 0.05
- ADMA 0.16
- Stochastic Oscillator
- VNOM 58.37
- ADMA 83.62
About VNOM Viper Energy Inc.
Viper Energy Inc is focused on owning and acquiring mineral and royalty interests in oil and natural gas properties primarily in the Permian Basin. The Permian Basin is known to have a number of zones of oil and natural gas-bearing rock throughout.
About ADMA ADMA Biologics Inc
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.